Hype Stories
Do you have a personal attachment to Agilent Technologies?
 | 3 days ago at Macroaxis By Vlad Skutelnik |
Agilent Technologies, a key player in the Life Sciences Tools & Services sector, is generating buzz among investors looking for promising additions to their portfolios. With a current valuation market value of $133.84, the stock is hovering close to its real value of $135.57, suggesting a fair pricing in the market. Analysts have set a target price range between $123.53 and $150.68, with a consensus leaning towards a "Buy" recommendation. Continue Reading...
- A Agilent Technologies
- Latest Insider Trading
- A 138.14 3.77
- Low 134.24
- High 139.0
- Volume 2.3 M
- Alpha -0.13
- Beta 0.54
- Return On Equity 0.25
- Return On Asset 0.0758
- Profit Margin 0.22 %
- Operating Margin 0.25 %
- Current Valuation 39.8 B
- Shares Outstanding 287.33 M
- Shares Owned By Insiders 0.28 %
- Shares Owned By Institutions 91.25 %
- Number Of Shares Shorted 3.46 M
- Price To Earning 37.55 X
- Price To Book 6.55 X
- Price To Sales 5.94 X
- Revenue 6.51 B
- Gross Profit 3.46 B
- EBITDA 1.49 B
- Net Income 1.29 B
- Cash And Equivalents 1.05 B
- Cash Per Share 3.57 X
- Total Debt 2.78 B
- Debt To Equity 0.52 %
- Current Ratio 2.03 X
- Book Value Per Share 20.53 X
- Cash Flow From Operations 1.75 B
- Short Ratio 2.59 X
- Earnings Per Share 4.81 X
- Price To Earnings To Growth 3.82 X
- Target Price 148.76
- Number Of Employees 17.4 K
- Beta 1.07
- Market Capitalization 38.61 B
- Total Asset 10.76 B
- Retained Earnings 782 M
- Working Capital 2.58 B
- Current Asset 3.63 B
- Current Liabilities 945 M
- Annual Yield 0.01 %
- Five Year Return 0.73 %
- Net Asset 10.76 B
- Accumulation Distribution 77804.7
- Daily Balance Of Power 0.792
- Rate Of Daily Change 1.03
- Day Median Price 136.62
- Day Typical Price 137.13
- Price Action Indicator 3.4
- Period Momentum Indicator 3.77
- Relative Strength Index 44.45
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Gabriel Shpitalnik
If you're contemplating adding more shares of Exicure (NASDAQ: XCUR) to your portfolio, there's a compelling case to consider. Despite the company's current lack of significant operations, its recent price surge of 69.24% signals a wave of investor interest that could present lucrative opportunities. With a potential upside of 41.25, the stock's volatility, reflected in a high coefficient of variation of 474.9, might appeal to those willing to ride the wave of market excitement for potentially substantial returns.
Key Discoveries
Exicure has a performance score of 19 out of 100, indicating room for improvement.| few days ago at Macroaxis By Aina Ster |  |
All that glitters is not gold, but Yatra Online might just be the exception. As a player in the travel services industry, this NASDAQ-listed company has been catching the eye of investors with its potential for growth. Despite a recent loss, the stock's valuation hype value stands at 1.4, suggesting that market sentiment is optimistic.
| over a week ago at Macroaxis By Vlad Skutelnik | |
Advent Technologies Holdings has an asset utilization ratio of 13.99%, meaning it generates $0.14 in revenue for every dollar of assets. This indicates efficient use of its assets in daily operations. Approximately 17% of the company's shares are owned by insiders, suggesting a strong internal stake.
| over two weeks ago at Macroaxis By Vlad Skutelnik | |
Chromadex Corp has earned a "Strong Buy" rating from five analysts. To enhance this expert consensus, we offer trading advice through our advanced recommendation system. This system evaluates the company's growth potential by analyzing both technical and fundamental data.
| over two weeks ago at Macroaxis By Rifka Kats |  |
With Singular Genomics Systems' stock showing a modest price change of 0.69 and a high price of 23.26, private investors might find December an opportune moment to reassess their positions, especially considering the company's EPS estimate for next year is projected as a loss of 31.72.
Top Findings
The asset utilization ratio measures how much revenue a company generates for every dollar of assets it holds. Singular Genomics Systems has a ratio of 1.1%, meaning it earns $0.011 for each dollar of assets. A rising asset utilization ratio suggests the company is becoming more efficient in using its assets for daily operations.| over two weeks ago at Macroaxis By Vlad Skutelnik | |
Strike while the iron is hot, but with North European Oil Trust (NRT), it might be wise to tread carefully. As we step into November, the energy sector's volatility is palpable, and NRT's recent performance reflects this uncertainty. With a potential downside price of $2.80 and a valuation real value slightly higher at $5.36, the stock's current market value of $5.14 suggests a tightrope walk between risk and reward.
| over three weeks ago at Macroaxis By Gabriel Shpitalnik |  |
Spirit Airlines, trading under the ticker NYSE: SAVE, has been a topic of discussion among investors considering whether to bolster their positions. Despite its presence in the competitive airlines industry, Spirit Airlines has faced financial turbulence, reporting a loss that has raised eyebrows among analysts. The stock's current day median price hovers around $2.87, with a typical price slightly higher at $2.94, indicating some variability in its daily trading pattern.
| over a month ago at Macroaxis By Vlad Skutelnik | |
Our trading recommendations work alongside the latest insights from analysts and experts on ICICI Bank Limited. By examining a wide range of data—fundamental, technical, and market-related—we assess the bank's growth potential.
Key Points
ICICI Bank's stock, trading at a quote of 29.6, has seen a price percent change of 2.49, indicating a positive momentum that could attract investors looking for growth in the Banks - Regional sector. With an accumulation distribution of 31.4K, the stock shows strong buying interest, suggesting potential for further upward movement.| over a month ago at Macroaxis By Ellen Johnson |  |
Comerica (NYSE: CMA) is catching the eye of investors who are increasingly optimistic about its potential. With a Sortino Ratio of 0.0377, the stock is showing a promising risk-adjusted return, which suggests that it could be a smart play for those looking to balance risk and reward. As the stock opened at 62.32 and reached a high of 63.27, there's a palpable sense of momentum that could translate into tangible gains for those willing to ride the wave.
Primary Takeaways
Macroaxis offers an impartial investment recommendation for Comerica, designed to complement existing analyst and expert opinions.| over a month ago at Macroaxis By Raphi Shpitalnik |  |